Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Chinese Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 12 Apr 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms BALISTAD-CN
- Sponsors Sanofi
- 04 Mar 2024 Status changed from active, no longer recruiting to completed.
- 25 Jan 2024 Planned End Date changed from 23 Feb 2024 to 28 Feb 2024.
- 25 Jan 2024 Planned primary completion date changed from 23 Feb 2024 to 28 Feb 2024.